AIM ImmunoTech Inc. (AIM) is a publicly traded Healthcare sector company. As of May 21, 2026, AIM trades at $0.26 with a market cap of $6.36M and a P/E ratio of -0.05. AIM moved -38.69% today. Year to date, AIM is -80.10%; over the trailing twelve months it is +102.64%. Its 52-week range spans $0.06 to $20.33. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces AIM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AIM ImmunoTech Raises $2.4 Million via 7.52 M Shares and 15 M Series I Warrants: AIM ImmunoTech will sell 7.52 million common shares at $0.325 each in a registered direct offering to raise $2.4 million before fees. It issued Series I warrants for 15.04 million shares at a $0.325 exercise price, exercisable for five years to fund clinical supply, Phase 3 trials and working capital.
| Metric | Value |
|---|---|
| Price | $0.26 |
| Market Cap | $6.36M |
| P/E Ratio | -0.05 |
| EPS | $-8.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.33 |
| 52-Week Low | $0.06 |
| Volume | 11.72M |
| Avg Volume | 0 |
| Revenue (TTM) | $88.00K |
| Net Income | $-13.96M |
| Gross Margin | 0.00% |
1 analysts cover AIM: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.